Literature DB >> 25773941

Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

Ijin Joo1, Jeong Min Lee, Dong Ho Lee, Ju Hyeon Jeon, Joon Koo Han, Byung Ihn Choi.   

Abstract

OBJECTIVES: To determine which dynamic phase(s) of gadoxetic acid-enhanced MRI is most appropriate to assess "washout" in the noninvasive diagnosis of hepatocellular carcinoma (HCC) based on hemodynamic pattern.
METHODS: In this retrospective cohort study, 288 consecutive patients with chronic liver disease presented with 387 arterially enhancing nodules (292 HCCs, 95 non-HCCs) (≥1 cm) on gadoxetic acid-enhanced MRI. All HCCs were confirmed by histopathology or by their typical enhancement pattern on dynamic liver CT. MR imaging diagnosis of HCC was made using criteria of arterial enhancement and hypointensity relative to the surrounding parenchyma (1) on the portal-venous phase (PVP), (2) on the PVP and/or transitional phase (TP), or (3) on the PVP and/or TP, and/or hepatobiliary phase (HBP).
RESULTS: For the noninvasive diagnosis of HCC, criterion 1 provided significantly higher specificity (97.9%; 95% confidence interval, 92.6 - 99.7%) than criteria 2 (86.3%; 77.7 - 92.5%), or 3 (48.4%; 38.0 - 58.9%). Conversely, higher sensitivity was obtained with criterion 3 (93.8%; 90.4 - 96.3%) than with criterion 2 (86.6%; 82.2 - 90.3%) or 1 (70.9%; 65.3 - 76.0%).
CONCLUSIONS: To make a sufficiently specific diagnosis of HCC using gadoxetic acid-enhanced MRI based on typical enhancement features, washout should be determined on the PVP alone rather than combined with hypointensity on the TP or HBP. KEY POINTS: • Gadoxetic acid-enhanced MRI enhancement features can be used to diagnose HCC. • Washout should be determined on the PVP alone for high specificity. • Hypointensity on the TP or HBP increases sensitivity but lowers specificity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773941     DOI: 10.1007/s00330-015-3686-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  51 in total

1.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

Review 2.  Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Authors:  Stefano Palmucci
Journal:  World J Hepatol       Date:  2014-07-27

3.  Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hironobu Sou; Katsuhiro Sano; Licht Tominaga; Ali Muhi; Tsutomu Araki
Journal:  Radiology       Date:  2010-07       Impact factor: 11.105

4.  Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI.

Authors:  Kathryn J Fowler; Arman Sheybani; Rex A Parker; Sean Doherty; Elizabeth M Brunt; William C Chapman; Christine O Menias
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

5.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

6.  Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features.

Authors:  Y Fukukura; J Taguchi; O Nakashima; Y Wada; M Kojiro
Journal:  J Comput Assist Tomogr       Date:  1997 Jan-Feb       Impact factor: 1.826

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate.

Authors:  Jhii-Hyun Ahn; Jeong-Sik Yu; Sung Ho Hwang; Jae-Joon Chung; Joo Hee Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  44 in total

Review 1.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 2.  LI-RADS 2017: An update.

Authors:  Ania Z Kielar; Victoria Chernyak; Mustafa R Bashir; Richard K Do; Kathryn J Fowler; Donald G Mitchell; Milena Cerny; Khaled M Elsayes; Cynthia Santillan; Aya Kamaya; Yuko Kono; Claude B Sirlin; An Tang
Journal:  J Magn Reson Imaging       Date:  2018-04-06       Impact factor: 4.813

Review 3.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

4.  Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.

Authors:  Dong Ik Cha; Kyung Mi Jang; Seong Hyun Kim; Tae Wook Kang; Kyoung Doo Song
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

Review 5.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

6.  Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters.

Authors:  Qi Tang; Cong Ma
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

7.  Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

Review 8.  Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

Authors:  Yvonne Purcell; Pauline Copin; Valérie Paradis; Valérie Vilgrain; Maxime Ronot
Journal:  Br J Radiol       Date:  2019-01-10       Impact factor: 3.039

9.  Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Víctor Sapena; Neus Llarch; Anna Darnell; Alba Díaz; Angeles García-Criado; Lluís Bianchi; Ramon Vilana; Álvaro Díaz-González; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

10.  Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command.

Authors:  Andreas Gutzeit; Simon Matoori; Johannes M Froehlich; Constantin von Weymarn; Carolin Reischauer; Orpheus Kolokythas; Matthias Goyen; Klaus Hergan; Matthias Meissnitzer; Rosemarie Forstner; Jan D Soyka; Aleksis Doert; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2015-11-16       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.